首页> 美国卫生研究院文献>Annals of the American Thoracic Society >Epidemiology of Vasopressin Use for Adults with Septic Shock
【2h】

Epidemiology of Vasopressin Use for Adults with Septic Shock

机译:成人败血症性休克使用加压素的流行病学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Rationale: Vasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock.>Objectives: We conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use.>Methods: This was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation.>Measurements and Main Results: Among 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2%) received vasopressin. A total of 6.1% of patients receiving vasopressin received vasopressin alone, and 93.9% received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6% over the study period, representing an average annual relative increase of 8% (P < 0.001). The median hospital rate of vasopressin use for septic shock was 11.7% (range, 0–69.7%). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age > 85 yr compared with the reference group of age < 50 yr; 95% confidence interval, 0.69–0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95% confidence interval, 3.20–3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37).>Conclusions: Approximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.
机译:>原理:加压素可用于治疗败血性休克中的血管扩张性低血压,但指南不建议将其用作一线或二线药物。关于目前在败血性休克中使用这种药物的频率知之甚少。>目标:我们进行了这项研究,以描述在美国大量患有败血性休克的成年人中血管加压素的使用方式,并确定患者和医院>方法:这是一项回顾性队列研究,研究对象为Premier医疗数据库(2008年7月至2013年6月)中因败血性休克而入住美国医院的成年人。我们在医院入院至少1天时与医院进行了多级混合效应Logistic回归分析,以鉴定与单独使用血管加压素或与其他血管加压素组合使用的相关因素。我们计算了Akaike信息标准(AIC)的商,以确定患者和医院特征对观察到的变化的相对贡献。>测量和主要结果:在532家医院的584,421名感染性休克患者中,有100,923名(占17.2%)接受加压素。总共6.1%接受加压素的患者单独接受加压素,93.9%的患者与其他加压素联合使用加压素(15种不同组合中多达5种加压素)。在研究期间,平均使用血管加压素的月率从14.5增加到19.6%,相当于每年平均相对增长8%(P <0.001)。接受加压素治疗败血性休克的中位住院率为11.7%(范围为0–69.7%)。患者的人口统计学和临床​​特征,包括患者年龄(年龄≥85岁的患者,调整后的比值比,为0.71,而年龄小于50岁的参考人群则为0.71; 95%置信区间,0.69-0.74)和急性呼吸功能障碍(校正后的比值比,3.25 ; 95%的置信区间为3.20-3.31),是观察到的加压素使用变化的大部分原因(AIC的商,0.56)。但是,入院医院对观察到的变化也有很大贡献(AIC的商为0.37)。>结论:败血症性休克患者中大约五分之一接受了加压素,但很少作为单一的加压素。加压素的使用随着时间的推移而增加。接受加压素的可能性与每个患者入院的具体医院密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号